<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01984580</url>
  </required_header>
  <id_info>
    <org_study_id>F/N-R-11-3038L</org_study_id>
    <nct_id>NCT01984580</nct_id>
  </id_info>
  <brief_title>Effect of Zinc on Barrett's Metaplasia</brief_title>
  <official_title>Effect of Zinc on Barrett's Metaplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Main Line Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sharpe-Strumia Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Main Line Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using orally administered zinc to patients already diagnosed with the pre-cancerous
      condition, Barrett's Esophagus, this study is asking two questions:

        1. can this zinc administration cause molecular-level changes in the Barrett's tissue?

        2. are the changes measured indicative of chemopreventive action by zinc regarding cancer
           progression?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      14 days prior to already-scheduled upper endoscopy (EGD) procedures for routine surveillance
      of Barrett's tissue, patients who have given written, informed consent are randomized (sealed
      envelope method) and placed on an oral dose of zinc gluconate (26.6 mg zinc BID) or a placebo
      (molar equivalent of sodium gluconate BID) for 14 days. At the time of endoscopy, 4 biopsies
      are taken (and pooled) from the Barrett's tissue and 4 from proximal normal esophageal
      tissue. Biopsies are flash frozen for later analyses by atomic absorption spectroscopy, PAGE
      and Western immunoblot or RNA microarray.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in zinc-regulated cellular proteins within Barrett's tissue</measure>
    <time_frame>in biopsy tissue after 14 days of Zn exposure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in cellular microRNA profile; changes in protein cancer biomarkers</measure>
    <time_frame>in biopsy tissue after 14 days of Zn exposure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Barrett's Metaplasia</condition>
  <arm_group>
    <arm_group_label>Zinc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sodium</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zinc gluconate</intervention_name>
    <description>26.6 mg zinc BID (as zinc gluconate)</description>
    <arm_group_label>Zinc</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:ages 18-80; prior diagnosis of Barrett's esophagus -

        Exclusion Criteria:unable to provide written, informed consent; prior history of Barrett's
        dysplasia or esophageal adenocarcinoma; drug exclusions: hormone replacement therapy,
        cholestyramine, amiloride diuretics, oral quinolone antibiotics, glucocorticoids,
        corticosteroids, anticoagulants (other than aspirin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>James M Mullin, Ph.D.</last_name>
    <phone>484-476-2708</phone>
    <email>mullinj@mlhs.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lankenau Institute for Medical Research</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2013</study_first_submitted>
  <study_first_submitted_qc>November 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2013</study_first_posted>
  <last_update_submitted>November 8, 2013</last_update_submitted>
  <last_update_submitted_qc>November 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Main Line Health</investigator_affiliation>
    <investigator_full_name>James M. Mullin, Ph.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Barrett's esophagus</keyword>
  <keyword>Esophagus</keyword>
  <keyword>Adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metaplasia</mesh_term>
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zinc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

